PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

It's Time to Revisit Nuvilex, Inc. and its Cell-in-a-Box® Live-Cell Encapsulation Technology for Cancer & Diabetes Treatments

Nuvilex, Inc. (OTCQB: NVLX) just might be the biggest steal in the market right now... period! If you're looking for a pure "diamond in the rough" to invest in, a true blockbuster opportunity in the making... Nuvilex, Inc. is the biotechnology for you.

We introduced NVLX to our subscribers back when it was less than .05/share in February 2013. It moved soon after into the teens where it traded in a channel from .10 to .17 for quite some time before heading to its high of .62 on news of funding... and it got there quickly once that news hit!!

If funding news was the impetus behind new highs at Nuvilex in early 2014, then you're in for the potential ride of your life with the news that current shareholders are eagerly anticipating. The significance to all of our subscribers who have yet to jump on board is that today's share price offers an excellent entry point ahead of what should be the company's biggest news ever.

After hitting .62 in Q1 2014, the stock price dwindled back down below .20 after the company went through a long lull in telling its story while it pieced together a number of big contracts and got its ducks in a row for what Nuvilex is now on the precipice of accomplishing. They are back to telling their story and releasing one big news item after another, and the price has moved from .168 to .25 where it hit Friday before settling at .2389 at the Close.

Anyone who invests in biotech stocks knows that hitting a number of key milestones equates to a number of big price movements upwards! Nuvilex has quite a few big milestones that it will be announcing soon... and for our subscribers, you can get in before the milestone announcements start unfolding.

Here is a quick look ahead at what we think will move Nuvilex's price back up to new highs and beyond in the very near future:

The company entered into pre-clinical studies with world renowned oncologist, Dr. Daniel Von Hoff at Translational Drug Development or TD2 which is quite possibly the premiere oncology CRO in the country if not the world. These pre-clinical studies to study the symptoms associated with abdominal cancers like pancreatic cancer, liver cancer, ovarian cancer, etc, are still in progress, and the longer they go on, the better Nuvilex's technology is apparently working.

This is truly a case of no news is good... make that great news!

In the study, 4 groups of mice were injected with ovarian cancer which is a very aggressive cancer. The study is to determine if Nuvilex's Cell in a Box technology can slow the onset and accumulation of ascites, a fluid that builds up in the abdominal cavity of those patients with an abdominal cancer. The fluid is often seeded with cancer cells and can create more tumors in the patient as the fluid builds up throughout the abdominal cavity.

The mice in Group 1 were the control group, the 2nd group was given a current drug on the market used to treat this symptom, the 3rd group was given Nuvilex's treatment which combines the Cell in a Box technology with the anticancer prodrug ifosfamide, and finally the 4th group was given Nuvilex's treatment plus the already marketed drug on the market.

Current shareholders are waiting on the results from this pre-clinical study. If the results are as good as many expect them to be, then Dr. Daniel Von Hoff could go to the FDA and request a short (3 to 6 months) Phase I/II human clinical trial and then request an accelerated approval for Nuvilex's treatment to improve the quality of life for those patients with abdominal cancers.

One week ago, Nuvilex applied to the FDA for the Orphan Drug Designation for its pancreatic cancer treatment.

The company has also applied to the EMA (European Medicines Agency), the equivalent to the FDA in Europe for the same Orphan Drug Designation. Nuvilex expects to learn this year (2014) if it will be awarded the designation from the EMA, which should create quite a stir for this small biotech.

Nuvilex has announced that it expects to begin its Phase 2b or "mini Phase 3" in the first quarter of 2015. The start of these trials will, of course, be preceded by a number of big announcements related to the start of those late phase trials.

Late last week... Nuvilex announced that it has secured the worldwide license for an insulin-producing cell line that will be tested to determine if the cell line can be encapsulated in Cell in a Box and serve as the company's diabetes treatment.

With what seems like an entire biotechnology sector engaged in a race to develop a diabetes treatment, Nuvilex may have just taken the lead. There are two sides forming in the race: Those companies, universities and organizations who are trying to develop a delivery system for a treatment, and those who are trying to develop a cell line or treatment to deliver to the hundreds of millions around the world who suffer with the disease.

Nuvilex may now have both if this recently obtained cell line proves successful!!! We expect pre-clinical and clinical trials to be announced which could capture the attention of the national media given Nuvilex may have just catapulted itself into the lead among many company's trying to develop a treatment.

It is becoming more and more clear to us that Nuvilex could very well be a buy-out candidate sooner rather than later... and if the company receives blockbuster results (which we fully expect) from its pre-clinical studies that could come at any time now... and when (not if) the company receives the Orphan Drug Designation from the FDA and EMA, we expect the talk of a buy-out to heat up.

Cancer and Diabetes breakthroughs... priced at .20-something/share... Don't wait too long to put Nuvilex back on your radar or to build a position. We feel Nuvilex is going to be that biotech which comes along every once in a while and the market takes a chance on it as a "diamond in the rough" and then cashes in on it — big!


Recent Gains for Subscribers:

LOTE - 2500%

IOGA - 1825%

FVRG - 1650%

NVLX - 1139%

PLPL - 1257%

LIVE - 530%


Disclaimer: The assembled information disseminated by Stock Market Media Group is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Stock Market Media Group does not expect that investors will buy and sell securities based on information assembled and presented in Stock Market Media Group's newsletter. Always do your own due diligence, and consult your financial adviser. Never invest in any stock mentioned in emails or a Stock Market Media Group newsletter unless you can afford to lose your entire investment. All assembled information within Stock Market Media Group is subject to change without notice. The assembled information within Stock Market Media Group is based on information supplied by the companies we highlight, press releases, SEC filings, or from other sources believed to be reliable as of the date of the report on the discussed companies, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Stock Market Media Group and its affiliates are not brokers, broker-dealers, market makers, investment bankers, analysts or underwriters. Stock Market Media Group may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profiled which is an inherent conflict of interest in Stock Market Media Group statements and opinions and such statements and opinions cannot be considered independent. Stock Market Media Group and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company's profile. Any and all compensation received in cash will always be disclosed here: Stock Market Media Group was not compensated for the research, writing, production, and release of this Newsletter on NVLX. Stock Market Media Group never accepts compensation in free-trading shares for its content development and awareness services of the company being profiled, but Stock Market Media Group does accept restricted shares for consulting work it does not related to its content development work. Also, when/if a third party compensates Stock Market Media Group, that third party may hold free-trading shares of the company being profiled and could very well be selling shares of the company's stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile, our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.


Nuvilex, Inc. Disclosure: A principal at SMMG currently owns 200,000 total shares of Nuvilex issued by the company through a consulting agreement which has since ended for work unrelated to its content development. The shares have been held for the requisite period under Rule 144 as of April 30, 2014, and are eligible to be sold immediately without further notice. To date none of the 200,000 shares has been sold.

http://us4.campaign-archive2.com/?u=39c1baafca0ca88a1e89940ba&id=1b670726c1